We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves BMS’ Opdivo As First-Line Treatment of Gastric Cancer
FDA Approves BMS’ Opdivo As First-Line Treatment of Gastric Cancer
The FDA has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) in combination with chemotherapy as a first-line treatment for patients with gastric and esophageal cancers.